Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
General15 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General21 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay
-
Noosa News23 hours agoBetty’s Burgers National Burger Day
-
General15 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire